JP2024511419A - 非結核性抗酸菌肺疾患を治療するための併用療法 - Google Patents

非結核性抗酸菌肺疾患を治療するための併用療法 Download PDF

Info

Publication number
JP2024511419A
JP2024511419A JP2023558149A JP2023558149A JP2024511419A JP 2024511419 A JP2024511419 A JP 2024511419A JP 2023558149 A JP2023558149 A JP 2023558149A JP 2023558149 A JP2023558149 A JP 2023558149A JP 2024511419 A JP2024511419 A JP 2024511419A
Authority
JP
Japan
Prior art keywords
days
amikacin
patient
active agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511419A5 (enExample
Inventor
ローズ，サーシャ
パーキンズ，ウォルター，アール．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of JP2024511419A publication Critical patent/JP2024511419A/ja
Publication of JP2024511419A5 publication Critical patent/JP2024511419A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023558149A 2021-03-24 2022-03-24 非結核性抗酸菌肺疾患を治療するための併用療法 Pending JP2024511419A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165418P 2021-03-24 2021-03-24
US63/165,418 2021-03-24
PCT/US2022/021706 WO2022204376A1 (en) 2021-03-24 2022-03-24 Combination therapy for treating non-tuberculous mycobacterial lung disease

Publications (2)

Publication Number Publication Date
JP2024511419A true JP2024511419A (ja) 2024-03-13
JP2024511419A5 JP2024511419A5 (enExample) 2025-04-01

Family

ID=83397862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558149A Pending JP2024511419A (ja) 2021-03-24 2022-03-24 非結核性抗酸菌肺疾患を治療するための併用療法

Country Status (4)

Country Link
US (1) US20250082570A1 (enExample)
EP (1) EP4313066A4 (enExample)
JP (1) JP2024511419A (enExample)
WO (1) WO2022204376A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017515913A (ja) * 2014-05-15 2017-06-15 インスメッド， インコーポレイテッド 非結核性抗酸菌肺感染症を治療するための方法
US20180360854A1 (en) * 2017-06-16 2018-12-20 Institute of Rheological Functions of Food Uses of ether phospholipids in treating diseases
JP2019500318A (ja) * 2015-11-18 2019-01-10 インスメッド インコーポレイテッド 細菌感染症を治療するための組成物及び方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9333214B2 (en) * 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
PL2852391T3 (pl) * 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
US20160175553A1 (en) * 2013-07-17 2016-06-23 Insmed Incorporated Low resistance aerosol exhalation filter
MX2021002503A (es) * 2018-09-04 2021-06-15 Paratek Pharm Innc Métodos de tratamiento de infecciones micobacterianas usando compuestos de tetraciclina.
WO2020123336A1 (en) * 2018-12-13 2020-06-18 Qrumpharma Inc. Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them
WO2022047292A1 (en) * 2020-08-31 2022-03-03 Insmed Incorporated Methods for treating newly diagnosed mycobacterium avium complex lung infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017515913A (ja) * 2014-05-15 2017-06-15 インスメッド， インコーポレイテッド 非結核性抗酸菌肺感染症を治療するための方法
JP2020055877A (ja) * 2014-05-15 2020-04-09 インスメッド インコーポレイテッド 非結核性抗酸菌肺感染症を治療するための方法
JP2019500318A (ja) * 2015-11-18 2019-01-10 インスメッド インコーポレイテッド 細菌感染症を治療するための組成物及び方法
US20180360854A1 (en) * 2017-06-16 2018-12-20 Institute of Rheological Functions of Food Uses of ether phospholipids in treating diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRIFFITH, D. E. ET AL: "Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacteriu", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 198, no. 12, JPN6026010188, 2018, pages 1559 - 1569, ISSN: 0005816574 *
SIEGEL, S. A. R. ET AL.: "Evaluation of Antimicrobial Susceptibility to Amikacin Liposome Inhalation Suspension and Relapse/Re", AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE ABSTRACTS, vol. A4495, JPN6026010190, 2020, ISSN: 0005816576 *
SIEGEL, S. ET AL.: "A58.NON-TUBERCULOUS MYCOBACTERIA: OFFTHE BEATEN TRACK", AMERICAN THORACIC SOCIETYINTERNATIONAL CONFERENCE ABSTRACTS, vol. Vol.197, A7669, JPN6026010189, 2018, ISSN: 0005816575 *

Also Published As

Publication number Publication date
EP4313066A4 (en) 2025-02-19
WO2022204376A1 (en) 2022-09-29
EP4313066A1 (en) 2024-02-07
US20250082570A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
US12168021B2 (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
US20250082570A1 (en) Combination therapy for treating non-tuberculous mycobacterial lung disease
HK40111789A (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
HK40086177B (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
HK40086177A (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
HK1230985B (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
HK1230985A1 (en) Methods for treating pulmonary non-tuberculous mycobacterial infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250324

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260316